Table 2.
Drugs and targets for the new cell identity
| Therapeutic intervention (single/in combination | Clinical status of drug | Clinical outcome | Indications | Ref |
|---|---|---|---|---|
| AXL (receptor tyrosine kinase) | ||||
| SGI-7079/erlotinib | Preclinical | Mesenchymal-like NSCLC cells became more sensitive to erlotinib | Non-small cell lung cancer | [218] |
| TP-0903 | Phase Ia/Ib | Recruiting | Progressive solid tumors | NCT02729298 |
| BGB324/erlotinib | Phase II | Met the initial efficacy objective | Non-small cell lung cancer | NCT02424617 |
| Glutathione peroxidase 4 (GPX4) | ||||
| RSL3, ML210 | Preclinical | Specific drug-tolerant persister (DTP) eradication | – | [246] |